Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 269 participants.

Also called NCT02513303

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 269 participants (enrolled count) (from the registry)
Sponsor
Vascular Therapies, Inc. (from the registry)
Registry
  • NCT NCT02513303
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02513303. Randomized; triple masking; primary purpose prevention. Start 2015-11 (registry gives no type); primary completion 2021-06 (actual). Results posted on 2025-10-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes
Acronym
ACCESS
Condition
Complication of Renal Dialysis
Condition
End Stage Renal Disease
Condition
End Stage Kidney Disease
Condition
ESRD
Condition
Chronic Kidney Failure
Condition
Complication of Hemodialysis
Condition
Vascular Access Complication
Condition
Arteriovenous Fistula
Intervention (Drug)
Sirolimus
Intervention (Procedure)
AV Fistula Surgery
Intervention (Device)
Sirolimus-eluting Collagen Implant (SeCI)
Lead sponsor
Vascular Therapies, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02513303
Content hash
748edbe67b094d2ab4b6ff1af8eb246c83f5c4ba1e8ad8959230e7e96332de1a